Abstract
This study investigated the in vitro antiproliferative potential of Silibinin on human melanoma cells with a BRAF gene mutation. Cell viability was assessed through incubation with different concentrations (41, 104, 207, and 518 µM) for 48 hours, using the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), which involves the reduction of the tetrazolium salt. The inhibitory concentration (IC50) was determined to be 240 µM. Bright-field microscopy revealed loss of cell adhesion to the substrate, a characteristic feature of cell death by apoptosis, across the tested doses. These results highlight the need for further studies to elucidate the mechanism of action and confirm its clinical efficacy.

This publication has 12 references indexed in Scilit: